| Grant number: | 17/25290-2 |
| Support Opportunities: | Scholarships in Brazil - Post-Doctorate |
| Effective date (Start): | November 01, 2018 |
| Effective date (End): | March 09, 2022 |
| Field of knowledge: | Biological Sciences - Immunology - Applied Immunology |
| Principal Investigator: | Bryan Eric Strauss |
| Grantee: | Nayara Gusmão Tessarollo |
| Host Institution: | Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira (ICESP). Coordenadoria de Serviços de Saúde (CSS). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil |
| Associated research grant: | 15/26580-9 - Cancer gene therapy: strategic positioning for translational studies, AP.TEM |
Abstract Melanoma is the most aggressive type of skin cancer and has a high lethality. A growing number of works have shown the relevance and benefits of gene therapy in treating cancer, including melanoma. In this context, recent research points to vaccination involving neoantigens as a promising strategy in the treatment of this malignancy. Previous results from the research group conducted by Professor Bryan Strauss at the Viral Vector Laboratory (ICESP) have shown that the combined gene transfer of p19Arf and IFN² acts with synergism on the immune system promoting the attraction of neutrophils, natural killer cells and CD4+ T lymphocytes and CD8+, in addition to modulating the expression of genes involved in important cell signaling pathways such as the p53 pathway. However, the mechanisms of activation of the immune system have not been fully elucidated. Thus, we theorize that treatment with the adenoviral vectors may alter the expression of the neoantigens and these may present an important role in the induction of the immune response. Since there are already published articles that describe the neoantigens important for the lineage B16, we will start by evaluating alterations in the expression of these neoantigens upon treatment with the adenoviral vectors p19Arf and IFN², as well as their participation in the antitumor immune response. In addition, we seek to reveal the performance of these neoantigens as vaccinogenic agents when associated with treatment with p19Arf and IFN². This association is expected to provide regression of metastatic tumors in murine models of melanoma immunotherapy. | |
| News published in Agência FAPESP Newsletter about the scholarship: | |
| TITULO | |
| Articles published in other media outlets (0 total): | |
| More itemsLess items | |
| VEICULO: TITULO (DATA) | |
| VEICULO: TITULO (DATA) | |